Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

CAPR

Capricor Therapeutics Inc

Mar 13 • 04:00PM ET

30.50

-2.92 -8.74 %

Healthcare • Biotechnology • USA • NASD

Peers: NVS CRSP SRPT FATE RARE EDIT BLUE SGMO CLLS TVRD

| Held by: VTI IWM VXF IWO VTWO IWC ITOT VFMO VTWG FHLC

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-1.80	Insider Own	10.24%	Shs Outstand	54.40M	Perf Week	9.32%
Market Cap	1.66B	Forward P/E	-	EPS next Y	-0.46	Insider Trans	0.00%	Shs Float	48.83M	Perf Month	26.03%
Enterprise Value	1.58B	PEG	-	EPS next Q	-0.52	Inst Own	56.83%	Short Float	14.11%	Perf Quarter	6.38%
Income	-81.99M	P/S	149.08	EPS this Y	118.36%	Inst Trans	33.25%	Short Ratio	5.34	Perf Half Y	373.60%
Sales	11.13M	P/B	16.63	EPS next Y	-211.81%	ROA	-74.74%	Short Interest	6.89M	Perf YTD	5.68%
Book/sh	1.83	P/C	16.83	EPS next 5Y	-	ROE	-107.79%	52W High	40.37 -24.45%	Perf Year	138.47%
Cash/sh	1.81	P/FCF	-	EPS past 3/5Y	-24.12% -20.84%	ROIC	-83.42%	52W Low	4.30 609.30%	Perf 3Y	573.29%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	84.17%	Volatility	10.28% 7.36%	Perf 5Y	488.80%
Dividend TTM	-	EV/Sales	141.83	EPS Y/Y TTM	-69.35%	Oper. Margin	-778.80%	ATR (14)	2.28	Perf 10Y	41.20%
Dividend Ex-Date	-	Quick Ratio	3.59	Sales Y/Y TTM	-52.08%	Profit Margin	-736.62%	RSI (14)	58.74	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	3.59	EPS Q/Q	-41.63%	SMA20	8.53%	Beta	0.44	Target Price	54.44
Payout	-	Debt/Eq	0.21	Sales Q/Q	-100.00%	SMA50	17.73%	Rel Volume	2.01	Prev Close	33.42
Employees	160	LT Debt/Eq	0.17	Earnings	Mar 12 AMC	SMA200	115.21%	Avg Volume	1.29M	Price	30.50
IPO	Jun 20, 2002	Option/Short	Yes / Yes	EPS/Sales Surpr.	-21.81% -100.00%	Trades		Volume	2,598,393	Change	-8.74%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-30-25	Initiated	Alliance Global Partners	Buy	$20
Jun-26-25	Initiated	B. Riley Securities	Buy	$21
May-20-25	Initiated	Roth Capital	Buy	$31
Oct-21-24	Initiated	Piper Sandler	Overweight	$35
May-17-24	Initiated	Oppenheimer	Outperform	$14
Jan-05-24	Initiated	Cantor Fitzgerald	Overweight	$8
Oct-26-22	Initiated	Ladenburg Thalmann	Buy	$15
Dec-26-18	Downgrade	Maxim Group	Buy → Hold
Jan-26-18	Reiterated	H.C. Wainwright	Buy	$6.50 → $8.60
Sep-15-17	Reiterated	H.C. Wainwright	Buy	$2.15 → $6.50
Feb-13-17	Resumed	Rodman & Renshaw	Buy	$14
Jul-06-16	Resumed	H.C. Wainwright	Buy	$13
Jun-15-16	Initiated	ROTH Capital	Buy

Show Previous Ratings

Mar-12-26 11:07PM	Capricor Therapeutics Inc (CAPR) Q4 2025 Earnings Call Highlights: FDA Milestones and Financial ... (GuruFocus.com) -8.74%
04:27PM	Capricor: Q4 Earnings Snapshot (Associated Press Finance)
04:01PM	Capricor Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
09:00AM	Capricor Therapeutics Announces Late-Breaking HOPE-3 Data at the 2026 MDA Conference Demonstrating Significant Functional Benefits of Deramiocel for Duchenne Muscular Dystrophy (GlobeNewswire)
Mar-10-26 10:47AM	Capricor Therapeutics Stock Jumps As FDA Resumes Deramiocel Review (Benzinga) +9.04%
09:25AM	Loading…
09:25AM	Capricor Therapeutics Announces Establishment of New PDUFA Date for Deramiocel BLA (GlobeNewswire)
07:00AM	Xenon hits a home run in epilepsy; FDA restarts review of Duchenne cell therapy (BioPharma Dive)
Mar-09-26 01:32PM	What's Going On With Moderna, Capricor, Other Biotech Stocks On Monday? (Benzinga) +9.78%
01:15PM	Biotech Stocks Rally on Departure of Polarizing FDA Official (The Wall Street Journal)
08:30AM	Capricor Therapeutics to Present Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Update on March 12 (GlobeNewswire)
Mar-03-26 05:30AM	MAHA Is Bringing Chaos to Biotech Investment Beyond Just Vaccines (The Wall Street Journal)
Feb-24-26 09:00AM	Capricor Therapeutics Announces Late-Breaking Presentation at 2026 MDA Clinical and Scientific Conference (GlobeNewswire)
Jan-21-26 10:49AM	CAPR Updates FDA on Deramiocel BLA, Plans HOPE-3 CSR Filing in February (Zacks)
Jan-20-26 09:15AM	Capricor Therapeutics Provides Regulatory Update on Deramiocel BLA Following FDA Review of HOPE-3 Topline Data (GlobeNewswire)
Jan-09-26 06:01AM	Here's Why This Biotechnology Skyrocketed by 439% in December (Motley Fool) -6.69%
01:14PM	Loading…
Dec-18-25 01:14PM	Capricor Therapeutics, Inc. (CAPR): A Bear Case Theory (Insider Monkey)
Dec-16-25 04:05PM	Capricor Therapeutics and Parent Project Muscular Dystrophy to Host Webinar Highlighting Positive Phase 3 HOPE-3 Topline Results in Duchenne Muscular Dystrophy (GlobeNewswire)
Dec-05-25 10:34AM	CAPR Stock Skyrockets 282% in a Week: Here's What You Need to Know (Zacks) +5.87%
06:15AM	Capricor Therapeutics Announces Pricing of $150 Million Public Offering of Common Stock (GlobeNewswire)
Dec-04-25 04:01PM	Capricor Therapeutics Announces Proposed Public Offering of Common Stock (GlobeNewswire) -15.22%
Dec-03-25 01:03PM	Capricor Skyrockets 535% After Getting Vindication In Muscular Dystrophy (Investor's Business Daily) +371.07%
10:36AM	Biotech Stock Up Over 400% After Late-Stage Breakthrough (Schaeffer's Research)
07:20AM	Capricor Therapeutics Announces Positive Topline Results from Pivotal Phase 3 HOPE-3 Study of Deramiocel in Duchenne Muscular Dystrophy (GlobeNewswire)
06:10AM	Capricor soars on positive results for Duchenne cell therapy (BioPharma Dive)
Nov-24-25 09:00AM	Capricor Therapeutics Presents New Data Demonstrating a Scalable Framework for Loading Therapeutic Oligonucleotides into Exosomes at AAEV 2025 (GlobeNewswire) -19.30%
Nov-11-25 12:00AM	Capricor Therapeutics Inc (CAPR) Q3 2025 Earnings Call Highlights: Navigating Challenges and ... (GuruFocus.com) +11.51%
Nov-10-25 04:50PM	Capricor: Q3 Earnings Snapshot (Associated Press Finance) -6.24%
04:01PM	Capricor Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-04-25 06:05PM	CeriBell, Inc. (CBLL) Reports Q3 Loss, Beats Revenue Estimates (Zacks)
Nov-03-25 09:15AM	Capricor Therapeutics Publishes Peer-Reviewed Study in Biomedicines Describing the Mechanism of Action and Potency Assay for its Investigational Cell Therapy, Deramiocel (GlobeNewswire) -6.76%
09:15AM	Loading…
Oct-31-25 09:15AM	Capricor Therapeutics to Present Third Quarter 2025 Financial Results and Recent Corporate Update on November 10 (GlobeNewswire)
Oct-30-25 09:23AM	Capricor (CAPR) Moves 12.0% Higher: Will This Strength Last? (Zacks) -10.26%
Sep-26-25 06:45AM	Capricor (CAPR) Surges 5.3%: Is This an Indication of Further Gains? (Zacks) +8.74%
Sep-25-25 07:15AM	Capricor Therapeutics Provides Regulatory Update on Deramiocel Program for Duchenne Muscular Dystrophy Following Type A Meeting (GlobeNewswire) +5.33%
06:50AM	Capricor readies revised FDA pitch for Duchenne cell therapy (BioPharma Dive)
Sep-10-25 07:43AM	Capricor refutes FDAs DMD deramiocel rejection in public statement (Pharmaceutical Technology)
Sep-09-25 09:20AM	Capricor Therapeutics Responds to FDA Posting of Complete Response Letter (CRL) for Deramiocel (GlobeNewswire)
Sep-02-25 03:40AM	Capricor Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - CAPR (PR Newswire)
Aug-28-25 04:21PM	Investors in Capricor Therapeutics, Inc. (CAPR): Protect Your Rights - Contact Levi & Korsinsky Before September 15, 2025 (Newsfile)
Aug-25-25 09:22AM	Did You Lose Money on Capricor Therapeutics, Inc. (CAPR)? Levi & Korsinsky Urges Investors to Act Before September 15, 2025 (Newsfile) -7.04%
Aug-21-25 04:20PM	Shareholders of Capricor Therapeutics, Inc. (CAPR): Protect Your Rights Before September 15, 2025 - Contact Levi & Korsinsky (Newsfile)
Aug-18-25 09:00AM	Capricor Therapeutics Announces First Subjects Dosed in Phase 1 Clinical Trial of Novel Exosome-Based Vaccine (GlobeNewswire)
08:28AM	Capricor Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - CAPR (PR Newswire)
Aug-15-25 09:15AM	Capricor Therapeutics, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - CAPR (PR Newswire)
Aug-14-25 04:26PM	Capricor Therapeutics, Inc. (CAPR) Lawsuit - Investors Urged to Contact Levi & Korsinsky Before September 15, 2025 (Newsfile) -6.27%
Aug-12-25 09:30AM	Capricor Therapeutics Inc (CAPR) Q2 2025 Earnings Report Preview: What To Expect (GuruFocus.com)
03:05AM	Capricor Therapeutics Inc (CAPR) Q2 2025 Earnings Call Highlights: Navigating Challenges with ... (GuruFocus.com)
Aug-11-25 06:06PM	Capricor: Q2 Earnings Snapshot (Associated Press Finance) -13.84%
04:05PM	Capricor Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
11:01AM	Controversial FDA regulator back 12 days after resigning (Quartz)
06:22AM	Wall St futures steady, chip stocks slip on China sales deal (Reuters)
Aug-08-25 08:30AM	Capricor Therapeutics Announces Type A Meeting Scheduled with U.S. FDA (GlobeNewswire) +12.39%
Aug-07-25 06:35PM	Quanterix Corporation (QTRX) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
Aug-06-25 09:00AM	Capricor Therapeutics to Present Second Quarter 2025 Financial Results and Recent Corporate Update on August 13 (GlobeNewswire)
Aug-05-25 10:45AM	Capricor Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - CAPR (PR Newswire)
Jul-29-25 08:23AM	Shareholders of Capricor Therapeutics, Inc. (CAPR): Protect Your Rights Before September 15, 2025 - Contact Levi & Korsinsky (Newsfile)
Jul-28-25 09:00AM	Capricor Therapeutics and Parent Project Muscular Dystrophy to Host Webinar to Review Latest Developments in the Deramiocel Program for the Treatment of Duchenne Muscular Dystrophy (GlobeNewswire)
Jul-25-25 08:07AM	Capricor Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - CAPR (PR Newswire) +8.95%
Jul-22-25 04:26PM	Capricor Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - CAPR (Business Wire)
10:05AM	FDA Rejects Replimunes Skin Cancer Treatment, Shares Sink (Bloomberg)
Jul-21-25 04:46PM	Investors Urged to Contact Levi & Korsinsky for Information Before September 15, 2025 - Capricor Therapeutics, Inc. (CAPR) (Newsfile) -8.87%
Jul-14-25 11:33AM	FDA Rejects CAPR's Cell Therapy BLA for Genetic Disorder, Stock Tanks (Zacks)
Jul-11-25 10:50AM	Capricor Therapeutics Hammered On A Surprise FDA Rejection (Investor's Business Daily) -32.98%
06:30AM	Capricor Therapeutics Provides Regulatory Update on Deramiocel BLA for Duchenne Muscular Dystrophy (GlobeNewswire)
Jun-26-25 09:49AM	General Mills upgraded, Trade Desk downgraded: Wall Street's top analyst calls (The Fly)
Jun-25-25 12:15PM	No Ad Comm not necessarily positive for Capricor, says Roth Capital (TipRanks) +8.65%
11:05AM	Capricors deramiocel moves ahead without AdCom, says H.C. Wainwright (TipRanks)
08:56AM	Capricor (CAPR) Moves 20.4% Higher: Will This Strength Last? (Zacks)
Jun-24-25 09:00AM	Capricor Therapeutics Provides Regulatory Update on Deramiocel BLA for Duchenne Muscular Dystrophy (GlobeNewswire) +20.44%
Jun-21-25 09:30AM	Capricor Therapeutics announces four-year data from HOPE-2 OLE study (TipRanks)
Jun-20-25 09:25AM	Capricor Therapeutics Announces Positive 4-Year Data from HOPE-2 Open-Label Extension Study of Deramiocel in Duchenne Muscular Dystrophy (GlobeNewswire) -30.82%
Jun-17-25 09:00AM	Capricor Therapeutics Announces Orphan Drug Designation for Becker Muscular Dystrophy and Regulatory Progress for Duchenne Muscular Dystrophy Program (GlobeNewswire)
Jun-12-25 09:35AM	Capricor says FDA inspection brought Form 483 with several observations (TipRanks) +6.09%
Jun-11-25 09:25AM	Capricor Therapeutics Announces Key Regulatory Updates for its Duchenne Muscular Dystrophy Program (GlobeNewswire) -5.40%
May-21-25 11:22AM	Capricor Therapeutics, Inc.'s (CAPR): Analysts See 489% Upside Potential (Insider Monkey)
May-14-25 03:15AM	Capricor Therapeutics Inc (CAPR) Q1 2025 Earnings Call Highlights: Navigating Challenges with ... (GuruFocus.com) +5.07%
May-13-25 04:19PM	Capricor: Q1 Earnings Snapshot (Associated Press Finance)
04:05PM	Capricor Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
09:00AM	Capricor Therapeutics Appoints Michael Binks, M.D. as Chief Medical Officer (GlobeNewswire)
May-12-25 09:37AM	What To Expect From Capricor Therapeutics Inc (CAPR) Q1 2025 Earnings (GuruFocus.com) +12.15%
May-06-25 09:15AM	Capricor Therapeutics to Present First Quarter 2025 Financial Results and Recent Corporate Update on May 13 (GlobeNewswire) -29.13%
May-05-25 08:00AM	Capricor Therapeutics Announces Completion of Mid-Cycle Review Meeting with FDA on Deramiocel for the Treatment of Duchenne Muscular Dystrophy Cardiomyopathy (GlobeNewswire) -13.15%
Apr-21-25 05:02PM	Capricor Therapeutics Inc (CAPR) Q4 2024 Earnings Call Highlights: Navigating Financial ... (GuruFocus.com) +5.96% +16.53%
08:00AM	OmniAb Announces Two New Appointments to its Board of Directors (Business Wire)
Apr-01-25 09:00AM	Capricor Therapeutics to Present at the 2025 Piper Sandler Virtual Cardio Day (GlobeNewswire)
Mar-21-25 06:23PM	Capricor Therapeutics Inc (CAPR) Q4 2024: Everything You Need To Know Ahead Of Earnings (GuruFocus.com) -10.45%
Mar-20-25 04:41PM	Is Capricor Therapeutics (CAPR) a Worst High-Risk High-Reward Growth Stock to Buy? (InsiderMonkey) +17.51%
10:21AM	Q4 2024 Capricor Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-19-25 06:57PM	Capricor projects FDA priority review decision for deramiocel by August 2025 (SeekingAlpha) +5.25%
06:56PM	Capricor Therapeutics, Inc. (CAPR) Q4 2024 Earnings Call Transcript (SeekingAlpha)
05:15PM	Capricor Therapeutics (CAPR) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
04:17PM	Capricor: Q4 Earnings Snapshot (Associated Press Finance)
04:05PM	Capricor Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-18-25 09:31AM	Capricor Therapeutics announces long-term data from HOPE-2 OLE study (TipRanks) -9.86%
Mar-17-25 09:25AM	Capricor Therapeutics Announces Positive Data Demonstrating Long-Term Efficacy of Deramiocel for the Treatment of Duchenne Muscular Dystrophy (GlobeNewswire)
Mar-11-25 09:00AM	Capricor Therapeutics to Present Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Update on March 19 (GlobeNewswire)
Mar-10-25 09:13AM	FDA Accepts Biologics License Application for Duchenne Muscular Dystrophy Cardiomyopathy Treatment (PR Newswire)
Mar-07-25 09:25AM	Capricor Therapeutics to Present at Leerink's Global Healthcare Conference 2025 (GlobeNewswire) -5.70%
Mar-06-25 06:20PM	Capricor Therapeutics, Inc. (CAPR): A Bull Case Theory (Insider Monkey) +7.39%
Mar-04-25 11:21AM	Capricor Therapeutics Cell Therapy Goes Under Priority FDA Review For Duchenne Associated-Heart Condition (Benzinga)

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy ("DMD"), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
DUNBAR GEORGE W JR	Director	Dec 19 '25	Option Exercise	1.39	3,000	4,170	14,306	Dec 23 02:55 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CAPR

Capricor Therapeutics Inc

Upgrade your FINVIZ experience